TABLE 1A.
Patient characteristics (FLT3 mutated AML patients)
| Patient No. | Age (years) | Gender, male (M)/female (F) | Newly diagnosed (ND), Relapsed/Refractory (R/R) | Cytogenetics | Molecular alterations identified |
|---|---|---|---|---|---|
| 1 | 33 | F | ND | 46,XX,inv(12) (p11.2q13) | FLT3/ITD, NPM1 |
| 2 | 75 | F | ND | 46,XX | FLT3/ITD, NPM1 |
| 3 | 24 | F | ND | 47, XX, +8 | FLT3/ITD |
| 4 | 56 | M | ND | 46, XY | FLT3/ITD, ATRX, CCT6B, KMT2C (MLL3), NPM1, PTPN11, RAD21 |
| 5 | 50 | F | ND | 46, XX | FLT3/TKD, IDH2, DNMT3A |
| 6 | 35 | F | R/R | 46, XX | FLT3/ITD, NPM1 |
| 7 | 60 | M | R/R | 46, XY | FLT3/ITD |
| 8 | 36 | F | R/R | 46, XX | FLT3/ITD, NPM1, ATRX, ASXL1, RUNX1, TET2 |
| 9 | 30 | M | ND | 46, XY | FLT3/ITD, WT1 |
| 10 | 39 | M | ND | 46,XY,t(5;22)(q35;q11.2) | FLT3/ITD, NRAS, PDCD11, WT1 |
| 11 | 46 | M | NDx | 47,XY,+11 | FLT3/ITD, TET2, KMT2A, SRSF2 |
| 12 | 38 | F | NDx | 46, XX | FLT3/ITD, FLT3/TKD |